Richard Adler, MD, FACS, discusses corneal fluorescein staining data presented at AAO 2023 from the pooled analysis of 2 phase 3 studies.
This is a video synopsis/summary of a Post Conference Perspectives featuring Richard Adler, MD.
Adler discusses phase 3 trial results for Miebo (perfluorohexyloctane ophthalmic solution), a drug being evaluated for treatment of evaporative dry eye disease in patients with meibomian gland dysfunction.
The phase 3 study compared Miebo (perfluorohexyloctane ophthalmic solution) to a vehicle for the ability to improve signs and symptoms of dry eye. Signs were assessed by corneal staining. After 4 weeks of treatment, Miebo (perfluorohexyloctane ophthalmic solution) demonstrated statistically significant improvements in both signs and symptoms compared with the vehicle, which were sustained through 8 weeks.
Adler notes Miebo produced rapid effects by targeting evaporation, a mechanism of action not previously explored for dry eye treatment. With a favorable safety profile and novel mechanism, Miebo offers an important new treatment option for dry eye disease.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Gefurulimab for gMG Meets Key End Points in PREVAIL Trial
July 28th 2025The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and the secondary endpoints are Quantitative Myasthenia Gravis total score and Myasthenia Gravis Composite total score.
Read More